Background. Each vaccine for human papillomavirus type 16 (HPV16) has been developed on the basis of a single variant, and whether these vaccines can prevent infection due to naturally occurring variants was not clear.
protection is assumed to be mediated by L1-neutralizing antibodies, which can be detected in the sera and cervicovaginal secretions of naturally infected and vaccinated individuals [9] [10] [11] [12] . However, so far, a serologic correlation of protection has not been established, and the minimum antibody level required for clinical protection is unknown. Nonetheless, vaccinated persons have high levels of neutralizing antibodies, and no breakthrough infections due to HPV vaccine types have been reported in vaccinated persons.
The efficacy of the vaccines is critically dependent upon the integrity of type-specific neutralizing epitopes. Major neutralizing epitopes have been shown to be conformational sites that are located on the surface-exposed domains [13] [14] [15] [16] , where intragenotype variations happen to be localized [17] . Hence, it is reasonable to consider that variation in these domains may influence capsid recognition by HPV vaccine-derived antibodies [17] [18] [19] .
The effect that certain amino acid substitutions in L1 have on neutralization has not yet been fully clarified. Therefore, we sought to determine whether known monoclonal antibodies (MAbs) or guinea pig sera immunized with HPV vaccines were able to neutralize representative variants containing certain single substitutions. To make this determination, we first produced a series of infectious pseudovirions (PsVs) that contained enhanced green fluorescent protein (EGFP) reporter plasmid, which had been packaged by HPV16 L2 and L1 (L1L2 PsVs). We then used a previously described neutralization assay to assess the ability of a set of known MAbs and guinea pig sera immunized with HPV16 vaccines to neutralize the infectivity of this series of PsVs.
METHODS

Determination of Naturally Occurring Single Amino Acid Substitutions of HPV16 L1
The HPV16 packaging plasmid (p16LLw) containing the codon-optimized genes encoding L1 (HPV16 isolate 114K) and L2 (isolate 114B) was kindly provided by Dr John T. Schiller (National Cancer Institute, Bethesda, MD) [7, 20] . The L1 sequence of p16LLw was selected as a reference. A collection of 1204 naturally occurring HPV16 L1 sequences from the National Center for Biotechnology Information and Papilloma Virus Episteme was chosen for study. All 1204 sequences were separately aligned with the reference by using Bioedit software, and 124 naturally occurring HPV16 L1 sequences from China were chosen and aligned similarly.
Synthesis of Mutant Constructs
p16LLw was used as template to make the variants. The gene encoding L1 was directionally subcloned into the pEASY-T1 Cloning Vector (Transgen Biotech, Beijing, China). All variants were obtained by site-directed mutation with polymerase chain reaction (PCR) primers (Supplementary Table 1 ) and were subcloned from the pEASY-T1 into the KpnI and BspEI sites of p16LLw. Whether the PCR procedure had generated unintended mutations was confirmed by sequencing.
Generation of HPV16 Mutant L1L2 PsVs
293FT cells were grown in complete Dulbecco's modified Eagle's medium containing 10% fetal bovine serum, 2% HEPES, 1% nonessential amino acids, and 1% penicillin/streptomycin. The reporter plasmid pcDNA3.1-EGFP was constructed by inserting an EGFP reporter gene into the pcDNA3.1 vector (Invitrogen, Carlsbad, CA) [21] . HPV L1L2 PsVs representing each variant were generated and titrated as described previously [7, 21, 22] . The PsV titers were defined as 50% tissue culture infective doses, calculated with the Reed-Muench method [23] .
Expression Level of L1 in PsVs
The gene expression level of each mutant construct was estimated by L1 Western blot and Coomassie staining. All mutant PsVs, together with the reference PsVs (cells cotransfected with the original p16LLw and the reporter gene) and a negative control (cells transfected with the reporter gene only), were denatured in sodium dodecyl sulfate (SDS) disruption solution. The denatured samples (volume, 15 μL) were resolved electrophoretically on an 8% SDS polyacrylamide gel and were then transferred onto a polyvinylidene fluoride membrane for Western blot analysis. The membrane was blocked and probed with horseradish peroxidase-labeled sera (Zerun Biotech, Shanghai, China). The reaction was detected with enhanced chemiluminescence substrate (Pierce, Waltham, MA). For Coomassie staining, the SDS polyacrylamide gel was stained by the GelCode Blue Stain Reagent (Thermo Scientific, Waltham, Massachusetts), and then it was destained with distilled water.
Transmission Electron Microscopy
The PsVs in suspension were applied to carbon-coated 200-mesh grids for 5 minutes, washed once with phosphate-buffered saline, and negatively stained for 1 minute with filter-sterilized 2% phosphotungstic acid. Electron micrographs were taken with a JEOL JEM-1400 microscope at 80 kV (Supplementary Figure 1D) 
Sera From Immunized Guinea Pigs With HPV Vaccines
The animal study was approved by the Institutional Animal Care and Use Committee of National Institutes for Food and Drug Control. All animals were housed in accordance with relevant guidelines. Five HPV16 VLPs, which were kindly provided by Ruike Biotechnology (Jiangsu, China), Bowei Biotechnology (Shanghai, China), Health Guard Biotechnology (Beijing, China), Innovax Biotech (Xiamen, China), and Sino Biological (Beijing, China), were mixed with aluminum hydroxide adjuvant. A total of 10 μg of the aforementioned adjuvant-adsorbed VLPs or 125 μL of Gardasil (Merck, Whitehouse Station, NJ) and 250 μL of Cervarix (GlaxoSmithKline, London, United Kingdom), which contained 10 μg of HPV16 L1 VLPs, were delivered intramuscularly for each guinea pig (weight range, 200-220 g; sex, female), and 3 guinea pigs were immunized with each vaccine. At the same time, the aluminum hydroxide adjuvant was inoculated into 3 guinea pigs intramuscularly as a control. Immunization was repeated 3 times at 3-week intervals, and sera were obtained 3 weeks after the final immunization. All of the serum samples were inactivated before the first use.
Neutralization Assay
Neutralization of the infectious PsVs were assessed as described elsewhere [21, 22, 24, 25] . Briefly, the PsVs were mixed for 1 hour at 4°C with medium, serial dilutions of MAbs, or sera. 293FT cells were plated 4-6 hours before the mixtures were added with 1.5 × 10 4 cells/100 μL/well. The aforementioned combinations were transferred into cell culture plates preseeded with 293FT cells and incubated for 68-72 hours. After incubation, the numbers of fluorospots were counted with an ImmunoSpot reader. The MAbs and serum neutralization titers were defined as 50% maximal inhibitory concentrations and 50% maximal inhibitory dilutions, respectively, and calculated with the Reed-Muench method [23] .
The sensitivity of the FluoroSpot counts can be adjusted by changing the sensitivity parameter. When the sensitivity parameter was 200-230, the FluoroSpot counts have the best correlation with the flow cytometry results [22] . Therefore, 230 spots were used as the optimal sensitivity parameter for this assay. At this sensitivity, 200 fluorescent spots were chosen for all of the variant PsVs, to guarantee that equal numbers of each mutant were used.
RESULTS
Selection of Substitutions
HPV16 L1 is composed of a β-barrel core and the surface loops BC, DE, EF, FG, and HI [26] . Nearly all conformational epitopes are located on these outwardly facing loops. Therefore, it is reasonable to consider that a few substitutions of the loop residues can lead to changes of the viral surface antigen determinants in eliciting different antibodies, as well as to the disruption of binding with previously identified MAbs or with antibodies elicited following vaccination.
To study the phenotypic variation of HPV16 L1, 1204 naturally occurring sequences were analyzed. A total of 270 of 505 amino acid residues had natural mutations (range of mutation frequencies among the 1204 sequences, 0.08%-20.18%). Ten single amino acid substitutions involving 8 positions occurring in a frequency of ≥0.08% among the 1204 sequences were chosen. They were T353P (mutation frequency, 20.10%), H76Y (15.28%), T176N (15.12%), L474F (14.62%), A266T (12.13%), T389S (4.32%), S282P (2.82%), N181T (1.16%), N181S (0.33%), and T353I (0.08%). Furthermore, 142 L1 sequences isolated from China were analyzed. In total, 46 residues had natural mutations (range of mutation frequencies, 0.81%-11.29%). Nine single mutants with a frequency of ≥0.81% among the 142 Chinese sequences but <1.0% among the 1204 global sequences were selected, including T301P (mutation frequency, 5.65%), D202H (3.23%), E352K (3.23%), K467R (2.42%), G483R (2.42%), A9Y (1.61%), K361E (1.61%), S302L (0.81%), and S302P (0.81%). These 19 substitutions were called "hot substitutions. "
Previous studies found that mutants on 35 positions of L1 may influence antigenic epitopes [27] [28] [29] [30] [31] [32] . Compared with the 1204 sequences, 20 of 35 positions were found to have 25 variations under natural conditions (Table 1 ). These 25 mutants were selected and called "epitope-related substitutions. " Five of them, including N181T/S, A266T, S282P, and K361E, were also hot substitutions. Hence, 39 mutants on 36 positions of L1 were selected to construct PsVs; their GenBank sequence numbers are listed in Supplementary Table 1 .
Generation and Infectivity Analysis of PsVs With Individual Amino Acid
Substitutions
To generate PsV constructs of the 39 variants, we used site-directed mutagenesis to generate mutations on p16LLw. Doublepass sequencing confirmed that the PCR procedure had not generated unintended mutations. Eight mutants could not form infectious PsVs (Supplementary Figure 1A) . Two of them (A9Y and E352K) expressed protein at a normal level and formed PsVs, as observed by electron microscopy (Supplementary Figure 1B and 1D ). It was possible that the PsVs of these 2 mutants are defective in binding, attaching, or entering 293FT cells. The 6 remaining mutants (T176N, D202H, T301P, S302P, T354I, and G483R) had no detectible protein and no detectible PsV formation with electron microscopy (Supplementary Figure 1B and 1D) . These substitutions most likely significantly reduced the expression level or stability of L1 and/or affected the assembly process of the PsVs.
The remaining 31 mutants were generated and titrated for evaluation by neutralization assays. Of those, 23 variants had a level of infectivity similar to that of the reference PsVs (generated from the original p16LLw). The 50% tissue culture infective doses of the other 8 mutant PsVs (G281W, S282P, N285H, S302L, C428W, K430Q, K430H, and K467R) were 1-3 orders of magnitude lower than those for the reference PsVs ( Figure 1 ). Correspondingly, 5 variants significantly decreased the expression of L1, with the exceptions being C428W, K430Q, and K430H (Supplementary Figure 1C) . These 3 substitutions did not affect the expression level of L1 and might instead affect the assembly process of the PsVs. All of the mutant PsVs had similar ratios of particles to infectivity, compared with the reference PsVs, except for C428W, K430Q, and K430H.
Sensitivity of PsVs of HPV16 Variants to a Panel of MAbs
A neutralization assay with a panel of 13 known neutralizing MAbs of HPV16 ( Figure 1 ) was performed to test whether the mutant PsVs could escape recognition by antibodies that neutralize the reference HPV16 L1 PsVs. When comparing neutralization titers of the MAbs, the neutralizing epitopes of the mutants were considered substantially different from those of the reference PsVs if the neutralization titer was ≥4-fold higher or lower. Ten of 31 variants had mean neutralization titers within 4-fold of the value for the reference PsVs, indicating that these single substitutions had no significant effect on neutralization by those MAbs. However, the remaining 21 mutants (P55L, P55-, A136T, A137S, N138K, A139E, N143K, N181S, A266T, G281W, S282P, A284V, N285H, N285T, S302L, T353P, K361E, T389S, C428W, K430Q, and K430H) showed substantially different neutralization titers from that of the reference PsVs ( Figure 1 ). Of these, 20 displayed a decreased sensitivity to at least 1 of the tested MAbs. Six of 20 mutants completely lost their susceptibility to neutralization by ≥1 MAb at a concentration of 50 μg/mL. Notably, 5 mutants displayed a >100-fold decrease in sensitivity to certain MAbs. Eight mutants displayed an increased sensitivity to neutralization by ≥1 MAb ( Table 2) .
The PsVs of P55L, P55-, C428W, K430H, and K430Q were less sensitive to neutralization by MAb 8A9 than the reference PsVs, which indicated that residues located near both terminals of L1 were important for the neutralization property by MAb 8A9. MAbs 4G12, 26H7, and 25F12 had decreased reactivity to 8 mutants-N138K, N143K, G281W, S282P, S302L, T353P, K361E, and K430Q substitutions-indicating that these MAbs may belong to 1 group. The same was observed for MAbs 22G5 and 17B10, which had decreased reactivity to 9 mutants (N138K, A139E, N143K, G281W, S282P, S302L, K361E, K430Q, and K430H) and increased reactivity to 2 mutants (A136T and A137S). The reactivity of MAb 6C7 was decreased for 10 mutants (A136T, A137S, N138K, A139E, A266T, N285H, N285T, S302L, K361E, and T389S), while the reactivity of 20G3 was decreased for 7 mutants (N138K, A139E, G281W, S282P, S302L, K361E, and K430Q). Only 1 of 31 mutants affected the neutralizing property of MAb 1D12, yielding an 8-fold reduction. The mutants N138K and K361E showed a decreased reactivity to MAb 5C10, whereas C428W increased its reactivity.
Ten mutants (A136T, N138K, A139E, N143K, G281W, S282P, N285H, N285T, S302L, and K361E) affected the neutralizing property of MAb 25H8, with N285H and N285T increasing its neutralizing reactivity. Six mutants (A139E, N143K, S302L, C428W, K430H, and K430Q) increased the sensitivity to neutralization by MAb 001, while P55-and N181S reduced the sensitivity ( Table 2) .
Analysis of the Neutralization Properties, Using Guinea Pig
Vaccinated Sera
The 31 HPV16 variant PsVs were tested against 21 sera from guinea pigs immunized with 7 HPV vaccines, with 3 guinea pigs assigned to each vaccine group. All sera neutralized all 31 HPV16 variants. However, variant PsVs containing the C428W and K430Q substitutions were less sensitive than the reference PsVs to neutralization by all of the vaccinated sera (Figure 2A ). 
Abbreviations: #, residues involving the conformational epitopes recognized by the specified monoclonal antibodies; …, residues not reported to be part of the conformational epitopes recognized by the specified monoclonal antibodies; -, variants who are not located on the secondary structures. a Calculated on the basis of 1204 sequences. 
Abbreviations: ↓, decrease in sensitivity to the tested MAbs caused by variants were within 100-fold; ↓↓, decrease in sensitivity to the tested MAbs caused by variants was >100-fold but still kept their susceptibility to neutralization by the tested MAbs; ↓↓↓, decrease in sensitivity to the tested MAbs caused by variants was >100-fold and completely lost susceptibility to neutralization by the tested MAbs; "↑" increase in sensitivity to the tested MAbs caused by variants was within 100-fold; …, change was within 4-fold.
Compared with the HPV16 reference PsVs, the C428W PsVs displayed a median 9-fold decreased sensitivity to vaccine-induced cross-neutralizing antibodies (P < .001, by the Wilcoxon paired signed rank test), whereas the K430Q PsVs displayed an 11-fold decreased sensitivity (P < .001; Figure 2B ). The residues C428 and K430 are located near the C-terminus of L1 and form part of the epitope of H16.U4 [32] .
DISCUSSION
Our study found that 31 of 39 HPV16 L1 variant constructs self-assembled efficiently into infectious PsVs. Among the 31 infectious mutants, there were obvious differences in PsV yields. Eight had a 50% tissue culture infective dose that was 1-3 orders of magnitude lower than that of the reference PsVs.
Of these 8 variants, substitutions in variants G281W, S282P, N285H, S302L, and K467R appeared yield lower protein levels, owing to either lower expression or reduced solubility, which was consistent with the previous study, in which variation in virion yield was attributed to sequence-specific differences in L1 yield [33] . Notably, although the detectible level L1 for 3 mutants, (G281W, S302L, and K467R) was extremely low, we observed their PsV particles with transmission electron microscopy, findings of which were consistent with their lower 50% tissue culture infective doses (Supplementary Figure 1C and  1D) . The cross-neutralization assays indicated that a single amino acid change could result in the loss of reactivity for a specific MAb, either because of the loss of direct interactions with the . Differences in the 50% maximal inhibitory dilution (ID 50 ) between variant pseudovirions (PsVs) and the reference PsVs against guinea pig sera. A, Serum samples were prediluted serially in 6 steps from 1:10 000 to 1:77 760 000. Each point represents the fold difference in ID 50 between a mutant and the reference PsVs. Reference PsVs with an ID 50 at least 4-fold higher or lower than that of the mutants were considered substantially antigenically different. B, Guinea pig sera were generated against the 7 vaccines targeting human papillomavirus 16 shown in the legend. ***P < .001, by the Wilcoxon paired signed rank test.
MAb or because of conformational changes that disrupt the interactions with MAb indirectly. Among the 31 variants that produced PsVs, the mutated residues are on 25 different amino acid positions. As expected, most of the 25 positions are located on the 5 surface loops ( Figure 3A and 3B). Most of these surface loop-located variants, such as N138K, A139E, N143K, G281W, S282P, and K361E, may change the epitope composition and directly change the interactions with antibodies. These single-residue substitutions yield amino acids that differ greatly in size (eg, A → E or G → W) or charge (eg, N → K and K → E), which should weaken/disrupt the interactions of the epitope with the related MAb, thus altering the sensitivity of the neutralization by that MAb. Naturally, the same amino acid position can be substituted to different residues. Among the 31 infectious variants, there are 5 such positions: N181T/N181S, N270S/N270T, N285H/ N285T, T353P/T353I, and K430H/K430Q. For the most part, 2 different mutations at the same position displayed different susceptibility to neutralization by MAbs or vaccinated sera, even for pairs with similar amino acid properties, such as T versus S, as in the case of N181T/N181S or N270T/N270S. However, in 1 pair of these mutants, N285H and N285T, the substituted H and T residues had different sizes and chemical properties, yet the 2 mutants had similar reductions in sensitivity to neutralization by 2 MAbs (6C7 and V5), displayed similar increases in the reactivity of MAb 25H8, and showed no significant changes in reactivity to other MAbs and the vaccinated sera. We could not understand the exact mechanisms why different susceptibilities were observed for similarly substituted mutant pairs (ie, N181T versus N181S and N270T versus N270S) or why similar susceptibilities were observed for a mutant pair involving a different substitution (ie, N285H versus N285T). However, these results suggest that subtle differences on the capsid protein can affect the binding to a specific epitope and, thus, affect neutralization by certain types of antibodies.
Our results indicated that sera immunized with HPV VLP vaccines had neutralizing activity against all 31 variants. These results, together with the fact that there are very few to no Figure 3A and also labeled.
breakthrough cases of HPV16 in vaccinated persons, provide evidence that these HPV16 variants would likely be protected against in vaccinated persons. The relative neutralization titer of a given serum against the reference, 114K, is quite similar to its relative titer against other variants, with the neutralizing activity involving ≤4-fold differences between 114K and the tested variants, except for C428W and K430Q, which had neutralizing activities 9-fold and 11-fold lower, respectively, than that for 114K. For practical consideration, the 4-fold differences in neutralization activity between 114K and the tested variants are within experimental error. However, the 9-fold and 11-fold reductions observed for C428W and K430Q, respectively, are considered to be significant. Furthermore, variant C428W also decreased neutralization by 3 MAbs, and K430Q decreased neutralization by 9 MAbs (Table 2) . Intriguingly, the susceptibilities of C428W and K430Q to neutralization by V5 were 9-fold and 30-fold lower, respectively, than that of the reference PsVs. C428 and K430 are not located on surface loops as part of the epitopes for any of these MAbs. C428/K430 are located near the end of a C-terminal helix (h4; Figure 3B ) that is shown to be critical for VLP assembly [13, 26, 34] , and C428 was also reported to be important for generating disulfide bond cross-linking with a neighboring L1 pentamer for VLP maturation [35] [36] [37] . Therefore, mutations of C428 and K430 are expected to affect VLP assembly/maturation and particle conformation. Thus, part of the PsVs of C428W/K430Q variants may not have optimal VLP conformation for binding by these MAbs. For binding of V5 to HPV16 virions, a previous study suggests that antigen-binding fragments of a V5 antibody may bind to 2 neighboring pentamers, with 1 in a pentavalent environment and 1 in a hexavalent environment ( Figure 3C ) [30] . Such binding of 2 adjacent pentamers by V5 on the VLP surface should be less effective if the VLP (or PsV) particles of C428W and K430Q are not assembled and matured into the optimal wide-type conformation, which explains why V5 is much less potent in neutralizing these 2 variant even though these 2 residues are not directly located within its mapped epitope area.
The V5 epitope area has been mapped to the residues on multiple surface loops (BC, FG, DE, and HI) from 2 neighboring L1 proteins [30] . Thirteen naturally occurring variants studied here (N138K, A139E, N143K, N181S, N181T, E269D, N270S, N270T, G281W, S282P, N285H, N285T, and K361E) are located on 10 sites within the mapped V5 epitope area ( Figure 3D ). Four of these 13 variants (N143K, G281W, N285H, and N285T) displayed decreased sensitivity to V5 reactivity, while 1 variant (N181S) showed increased sensitivity ( Figure 3D ). The remaining 8 variants (on 7 remaining positions) had no significant effects on the neutralization ability of MAb V5, suggesting that these residues are not directly involved in bonding with V5, even though they are located within the epitope area.
Taken together, these data suggest that HPV16 intragenotypic variants differ in their sensitivities to MAbs or antibodies induced by vaccines through directional change of epitope or subtle alteration of L1 surface features to affect antibody binding. The presence of serotypic divergence would suggest that individual genital HPV types are, similar to viruses such as influenza virus, undergoing antigenic drift of the type that alters seroreactivity to the virions. These findings, if substantiated by future studies using other sets of sera, may have important implications for the future design of effective broad-protective vaccines, as well as for designing vaccine efficacy trials. For future design of improved vaccines against HPV16 or other types, it may be desirable to use either a dominant variant VLP whose antisera can neutralize all prevailing variants or a multivalent vaccine containing several variants of the same type HPV VLPs.
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